Abstract: The present invention describes a new crystalline form of rifaximin, characterized in that it is a solvated form of rifaximin called rifaximin ?. The invention also describes a process for the preparation of rifaximin ?, a pharmaceutical composition comprising said rifaximin form, and its use for treating inflammations and infections.
Type:
Grant
Filed:
May 7, 2015
Date of Patent:
April 10, 2018
Assignee:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Paola Maffei, Annalisa Sforzini, Fabrizia Grepioni, Laura Chelazzi
Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.
Abstract: The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.
Type:
Grant
Filed:
April 24, 2014
Date of Patent:
November 22, 2016
Assignee:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Paola Maffei, Vittoria Lauro, Maria Barbanti, Donatella Confortini, Dario Braga
Abstract: The present invention relates to rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions and are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention also relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is from 1:1 to 10:1, together with pharmaceutically acceptable excipients. The present invention further relates to rifaximin crystals obtained by dissolving rifaximin and amino acids in solutions formed by ethanol/water and evaporating the solution.
Type:
Grant
Filed:
July 3, 2013
Date of Patent:
September 27, 2016
Assignee:
Alfa Wassermann S.P.A
Inventors:
Giuseppe Claudio Viscomi, Laura Chelazzi, Fabrizia Grepioni, Dario Braga, Maddalena Kindt
Abstract: The present disclosure relates to pharmaceutical or nutritional compositions containing ?-galactosidase and ?-galactosidase and their use in the prevention and/or treatment of gastroesophageal reflux disease; in particular the present disclosure related to pharmaceutical or nutritional compositions.
Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.
Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Type:
Grant
Filed:
April 25, 2014
Date of Patent:
March 1, 2016
Assignee:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Barbanti, Dario Braga
Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.
Abstract: The present invention describes sulodexide or at least one of its components for use in the reduction of circulating matrix metalloproteinase (MMPs), in particular MMP-9. Sulodexide and its composition are useful for the treatment of pathologies wherein the MMPs are involved, such as cardiovascular disease, cardiovascular disease caused by diabetes, varicose veins, chronic venous insufficiency (CVI), gastrointestinal ulcers, pulmonary disease, and neoplastic pathologies.
Type:
Grant
Filed:
April 20, 2011
Date of Patent:
March 24, 2015
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Claudio Viscomi, Ferdinando Mannello, Cristiana Bruno
Abstract: Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form ?, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days.
Type:
Application
Filed:
April 11, 2014
Publication date:
March 19, 2015
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Paola MAFFEI, Giuseppe BOTTONI, Maria GRIMALDI
Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.
Type:
Application
Filed:
April 28, 2014
Publication date:
March 12, 2015
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Paola MAFFEI, Milena BACHETTI, Giuseppe BOTTONI, Giuseppe Claudio VISCOMI
Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Type:
Application
Filed:
April 25, 2014
Publication date:
March 12, 2015
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria Miriam BARBANTI, Dario BRAGA
Abstract: Described herein are methods and systems for treatment and/or prevention of conditions associated with NSAID administration and related compositions.
Type:
Application
Filed:
April 11, 2014
Publication date:
October 16, 2014
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Maria GRIMALDI, Maria Vittoria FOGLI, Paola MAFFEI, Cecilia RENZULLI, Annalisa SFORZINI, Corrado BLANDIZZI, Carmelo SCARPIGNATO
Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
October 7, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Type:
Grant
Filed:
November 19, 2012
Date of Patent:
September 16, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
Abstract: The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.
Type:
Application
Filed:
April 24, 2014
Publication date:
August 21, 2014
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Paola MAFFEI, Vittoria LAURO, Miriam BARBANTI, Donatella CONFORTINI, Dario BRAGA
Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
Type:
Application
Filed:
December 4, 2013
Publication date:
July 3, 2014
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Ernesto PALAZZINI, Villiam ZAMBONI, Maria Rosaria PANTALEO
Abstract: Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: wherein: R is hydrogen or acetyl; R1 and R2 are independently selected from the group consisting of hydrogen, (C1-4) alkyl, benzyloxy, mono- and di-(C1-3) alkylamino-(C1-4)alkyl, (C1-3)alkoxy, (C1-4) alkyl, hydroxy-methyl, hydroxy-(C2-4)-alkyl, and nitro or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups and R3 is hydroxyalkyl (C1-4). In addition, processes to obtain these compounds are described.
Type:
Grant
Filed:
November 26, 2012
Date of Patent:
July 1, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Glaudio Viscomi, Manuela Campana, Mahena Folegatti, Paolo Righi, Vincenzo Cannata, Goffredo Rosini
Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.
Type:
Grant
Filed:
July 9, 2012
Date of Patent:
June 10, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Paola Maffei, Milena Bachetti, Giuseppe Bottoni, Giuseppe Claudio Viscomi